The treatment of low differentiated germinal cancers of the testis using mithramycin.
Twenty-six patients with metastases from a germinal cancer of the testis were treated with Mithramycin. After an observation time of between one-half-3 one-half years, 18 are still alive, of which 12 appear to be free from cancer. The 2-year survival rate is 50% (5/10). The side effects of Mithramycin therapy are described and discussed.
D004407:Dysgerminoma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D008926:Plicamycin / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014839:Vomiting / Q000139:chemically induced
D008926:Plicamycin